atai Life Sciences (ATAI) — atai Life Sciences stock slid around 9% in premarket trading after Recognify Life Sciences, an atai-backed company, reported that its Phase 2b trial of inidascamine for cognitive impairment associated with schizophrenia missed its primary endpoint.
The setback was a reminder of pipeline risk in atai's broader portfolio even as its lead 5-MeO-DMT program with Beckley Psytech advanced. Investors reacted to the miss as a negative read-through for that non-psychedelic asset.
Source: finance.yahoo.com
For the rest of that week's sector news, read our week in review.